Best Peptides for Weight Loss
Research peptides for weight loss span two fundamentally different categories: FDA-approved GLP-1 receptor agonists with Phase 3 trial data showing 15 to 22 percent body weight reduction in studied populations, and growth hormone secretagogues studied for body composition improvement and visceral fat reduction. This guide ranks the best peptides for weight loss by the strength of published evidence, explains the mechanisms behind each, and covers what clinical trial data shows about outcomes in the specific populations studied.
Semaglutide and Tirzepatide are the FDA-approved options with the deepest clinical evidence base for specific obesity indications. Retatrutide is an investigational triple agonist in ongoing trials and remains unapproved; its evidence should not be treated as equivalent to approved options. For GH-based body composition research without caloric restriction, CJC-1295 plus Ipamorelin is the most studied secretagogue combination, though human outcome evidence is limited.
Metabolic & Weight · Evidence Map
Best Peptides for Weight Loss
5 compounds ranked · Updated July 2026
The deepest clinical evidence in this registry for a regulated weight-management indication
- Dose
- Approved-product dosing is indication-specific and clinician-directed; not a research-use protocol
- Half-life
- ~7 days
Strong clinical evidence for a regulated metabolic indication with a dual GLP-1 plus GIP mechanism
- Dose
- Approved-product dosing is indication-specific and clinician-directed; not a research-use protocol
- Half-life
- ~5 days
An investigational example of multi-receptor metabolic research with published Phase 2 human data
- Dose
- Investigational-trial dosing only; not approved for self-directed use
- Half-life
- Long-acting weekly study design
A long-acting GHRH analogue plus selective secretagogue used to study GH-axis signaling and body composition endpoints
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- CJC DAC: ~8 days; Ipamorelin: ~2 hours
A research example of selective growth-hormone-fragment hypotheses studied in early metabolic trials
- Dose
- Research-study protocols vary; not dosing guidance
- Half-life
- ~30 minutes
What Weight Loss Peptide Research Actually Shows
- 1GLP-1 agonists do not burn fat directly. They work by reducing caloric intake through appetite suppression and slowed gastric emptying. The weight lost is from eating less, not from metabolic acceleration. This distinction matters because the clinical trial results are from populations under medical supervision; extrapolation to self-administered use is not supported by the evidence.
- 2Lean mass change on GLP-1 therapy varies by resistance training participation in the trial populations. STEP and SURMOUNT sub-analyses showed that participants with structured resistance training had better lean mass preservation. These findings come from specific monitored clinical settings and cannot be assumed to apply to unsupervised use.
- 3AOD-9604 did not meet its primary endpoint sufficiently to advance to Phase 3 in obesity. Its effects on fat mass were statistically significant but clinically modest. Most online guides omit this critical piece of context, presenting AOD-9604 as a proven fat-loss compound when the human trial evidence shows limited efficacy.
- 4Tirzepatide's superiority over semaglutide in the SURMOUNT-5 head-to-head trial comes from the GIP receptor component acting on adipocyte lipolysis and apparent reduction of compensatory energy conservation. These are findings from a specific supervised clinical trial population and do not generalize to unsupervised or off-label use.
- 5Retatrutide's Phase 2 trial data showed continued weight loss through the study period without the plateau observed in some semaglutide and tirzepatide analyses. Phase 3 results are not yet fully published. The compound remains investigational, and any specific percentage claims from Phase 3 interim data should be understood as preliminary until peer-reviewed publication.
Evidence-Ranked Comparison
| Peptide | Evidence | |
|---|---|---|
#1Semaglutide | Strong Evidence | Full Profile → |
#2Tirzepatide | Strong Evidence | Full Profile → |
#3Retatrutide | Moderate Evidence | Full Profile → |
#4CJC-1295 + Ipamorelin | Preliminary Evidence | Full Profile → |
#5AOD-9604 | Preliminary Evidence | Full Profile → |
Detailed Peptide Profiles
Semaglutide
Strong EvidenceFDA ApprovedGLP-1 RAPhase 3 DataThe deepest clinical evidence in this registry for a regulated weight-management indication
The STEP clinical trial program (STEP 1 through 5, published 2021-2022 in the New England Journal of Medicine) established semaglutide 2.4 mg for a specific obesity indication. STEP 1 showed 14.9 percent mean body weight loss at 68 weeks versus 2.4 percent for placebo (n=1961). STEP 4 showed that discontinuation leads to rapid weight regain, confirming ongoing treatment is necessary for weight maintenance. The SELECT cardiovascular outcomes trial (2023, n=17,604) demonstrated a 20 percent reduction in major adverse cardiovascular events in non-diabetic obese patients. These findings apply to the studied indication and population and do not support generalization to unrelated uses.
- FDA-approved (Wegovy for obesity)
- Robust Phase 3 RCT data (STEP program)
- Cardiovascular benefit confirmed in studied population (SELECT trial)
- Once-weekly approved formulations
- GI side effects (nausea, vomiting, constipation)
- Not a general wellness therapy
- Weight regain on discontinuation
- Counterfeit products are a documented risk
Tirzepatide
Strong EvidenceFDA ApprovedDual AgonistPhase 3 DataStrong clinical evidence for a regulated metabolic indication with a dual GLP-1 plus GIP mechanism
The SURMOUNT Phase 3 program (SURMOUNT-1, published NEJM 2022) showed 22.5 percent mean weight loss at 72 weeks on the 15 mg dose (n=2539) in the studied obesity population. SURMOUNT-4 (2023) confirmed rapid weight regain on discontinuation consistent with semaglutide data. A head-to-head trial (SURMOUNT-5, reported 2025) compared tirzepatide to semaglutide at 72 weeks, showing greater mean weight reduction. These findings apply to the studied indication and population and do not support generalization to cosmetic, sex-specific, or unregulated use.
- Superior weight loss vs semaglutide in head-to-head trial (studied population)
- Dual GLP-1 plus GIP mechanism
- FDA-approved (Zepbound)
- Regulated formulations exist
- GI side effects comparable to semaglutide
- Not a general-purpose peptide
- Requires medical assessment
- Unregulated supply is unsafe
Retatrutide
Moderate EvidenceInvestigationalTriple AgonistPhase 2 DataAn investigational example of multi-receptor metabolic research with published Phase 2 human data
Retatrutide is an investigational triple agonist (GLP-1, GIP, and glucagon receptors) in clinical development by Eli Lilly. Published Phase 2 data (NEJM 2023) showed substantial weight reduction at studied doses in an obesity population over 48 weeks. Phase 3 trials (the TRIUMPH program) are ongoing; their results are not yet fully published or peer-reviewed, and retatrutide remains unapproved. Specific percentage claims from interim or unpublished Phase 3 data should not be treated as established findings. It should not be represented as an approved option or as evidence for unrelated conditions.
- Published Phase 2 human trial program
- Distinct triple-agonist mechanism studied
- Useful for examining investigational trial design
- Investigational status; not approved
- Adverse-event profile still being characterized
- Phase 3 results not fully published
- Counterfeit risk from unregulated supply
CJC-1295 + Ipamorelin
Preliminary EvidenceResearch ChemicalGH SecretagogueBody CompositionA long-acting GHRH analogue plus selective secretagogue used to study GH-axis signaling and body composition endpoints
CJC-1295 (a GHRH analog with drug affinity complex modification) has been studied in Phase 2 trials showing sustained GH and IGF-1 elevation. Ipamorelin, a selective GHRP, amplifies GH pulses without the cortisol or prolactin elevation seen with less selective GHRPs. The combination drives GH-mediated lipolysis, particularly of visceral adipose tissue. Small human studies have shown improvements in body composition after multi-week protocols, though no large obesity-specific RCTs have been published. Published evidence is insufficient to establish clinically meaningful weight-loss outcomes.
- Human pharmacodynamic data on GH and IGF-1 changes
- Mechanism is relatively well described
- Useful GH-axis body composition research model
- Not FDA-approved
- Limited human RCT data specific to fat loss
- No broad approved indication
- Endocrine effects can be consequential
AOD-9604
Preliminary EvidenceResearch ChemicalHGH FragmentPreliminaryA research example of selective growth-hormone-fragment hypotheses studied in early metabolic trials
AOD-9604 is a growth-hormone fragment studied for metabolic effects. Phase 2b clinical trials (METAOD program, 2005-2007) showed modest but statistically significant effects on fat mass reduction in obese subjects over 12 weeks; the compound did not advance to Phase 3 for obesity. It received GRAS (Generally Recognized As Safe) status from the FDA in 2014 as a food ingredient at doses used in studies. Early human studies do not establish clinically meaningful weight-loss outcomes or a safe non-prescription role.
- Defined fragment biology
- Some clinical development history
- GRAS status at studied doses
- Useful translational case study
- Modest efficacy in Phase 2b; no Phase 3 program followed
- Very short half-life
- Marketing often exceeds trial results
- Not a substitute for clinical care
How to Choose the Right Peptide
| Your Goal | Best Choice |
|---|---|
| Understanding the strongest clinical evidence for obesity management | Semaglutide (Wegovy) literature |
| Comparing dual-incretin evidence with single-incretin data | Tirzepatide (Zepbound) literature |
| Understanding investigational multi-receptor metabolic research | Retatrutide trial literature |
| Studying GH-axis body composition research endpoints | CJC-1295 + Ipamorelin literature |
Research Background
How GLP-1 Receptor Agonists Produce Weight Loss
GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released from intestinal L-cells after eating. Synthetic GLP-1 receptor agonists like semaglutide and tirzepatide replicate and amplify this signal through multiple simultaneous mechanisms. First, they slow gastric emptying, which extends the physical feeling of fullness and reduces the rate at which nutrients enter the bloodstream. Second, they act directly on GLP-1 receptors in the hypothalamic arcuate nucleus and other brain regions that regulate appetite, producing a central reduction in hunger signals. Third, they modulate the mesolimbic reward pathway, reducing food cravings. Together these mechanisms reduce caloric intake in the studied populations. These mechanistic findings are specific to the clinical trial populations studied and the approved indications.
Tirzepatide's Dual Mechanism
Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, which head-to-head trial data confirmed translates into greater mean weight reduction versus semaglutide in the studied obesity population. The GIP receptor component contributes enhanced insulin secretion in a glucose-dependent manner, direct activation of GIP receptors on adipocytes to promote lipolysis, and modulation of adipose tissue energy storage. These mechanistic differences have clinical implications specific to the studied indication and do not generalize to off-label or wellness uses.
Retatrutide and the Glucagon Receptor: Investigational Mechanism
The defining feature that separates retatrutide from both semaglutide and tirzepatide is glucagon receptor agonism. Glucagon receptor activation in adipocytes and the liver drives thermogenesis (heat production from fat oxidation), increases basal metabolic rate, and promotes hepatic fat clearance. Phase 2 trial data (NEJM 2023) showed substantial weight reduction in the studied obesity population, with the weight loss continuing through the study period. Phase 3 trials (the TRIUMPH program) are ongoing, and their full results have not been published in peer-reviewed form. Retatrutide remains investigational and unapproved; its evidence should be understood in the context of ongoing trial development.
Growth Hormone Secretagogues for Body Composition
Growth hormone secretagogues work through a completely different mechanism from GLP-1 agonists and are better characterized as body composition research tools than as weight loss agents. GH drives lipolysis primarily in visceral adipose tissue, while simultaneously increasing protein synthesis and lean mass. The result is body composition change (less fat, more muscle) rather than simply lower scale weight. Tesamorelin, a stabilized GHRH analog with FDA approval for HIV-associated lipodystrophy, demonstrated visceral fat reduction in multiple RCTs with concurrent lean mass preservation in that specific indication. GH secretagogues like CJC-1295 plus Ipamorelin have published pharmacodynamic data but lack the large obesity-specific RCTs that would establish them for weight management. All GH secretagogues are prohibited by WADA in competitive sport.
Visceral Fat vs Subcutaneous Fat: Why It Matters for Research
Not all fat is metabolically equivalent. Visceral adipose tissue (VAT), which surrounds abdominal organs, is the metabolically active fat that drives insulin resistance, inflammation, cardiovascular disease risk, and metabolic syndrome. Subcutaneous fat, which sits under the skin, is less metabolically dangerous. GLP-1 receptor agonists reduce total body weight with proportional reductions in both fat types, though they tend to preferentially reduce visceral fat. GH secretagogues and tesamorelin specifically target VAT in their studied indications. For research purposes, DEXA scans or waist circumference measurement provide a more meaningful picture of fat reduction outcomes than BMI alone.
Lean Mass Considerations in GLP-1 Research
One important finding from the STEP and SURMOUNT trial programs is that a portion of weight lost on GLP-1 agonists comes from lean mass rather than fat mass. Sub-analyses from these trials showed varying lean-to-fat ratios depending on resistance training participation. This finding has led to research interest in body composition monitoring during GLP-1 therapy. DEXA scanning or waist circumference measurement provides a more accurate picture of fat loss versus lean mass change. These are research findings from the specific trial populations and should not be extrapolated to design self-administered protocols.
AOD-9604: Selective Lipolysis Without GH Side Effects
AOD-9604 represents an attempt to isolate the fat-burning function of growth hormone without its growth-promoting or insulin-desensitizing effects. The C-terminal fragment (residues 177-191) of human GH retains the ability to stimulate fat oxidation via beta-3 adrenergic receptor activation on adipocytes but does not bind IGF-1 receptors. Phase 2b trials showed modest but measurable effects on fat mass in obese subjects. Its GRAS status from the FDA distinguishes it from most research peptides in terms of the regulatory safety review it has undergone at studied doses. The main limitation is that its efficacy is more modest than full GH secretagogue stacks, and no Phase 3 obesity program was completed.
Regulatory Status and Research Context
Semaglutide (Wegovy for obesity, Ozempic for type 2 diabetes) and Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) are FDA-approved medications with well-characterized safety profiles from large clinical trial programs. Retatrutide remains investigational and unapproved; ongoing Phase 3 trials will determine whether it advances to regulatory review. AOD-9604 has FDA GRAS status at studied doses. CJC-1295, Ipamorelin, and the GHRP class are research chemicals not approved for human use in most jurisdictions. WADA banned GH secretagogues from competitive sports, which is relevant context for any athletic research applications.
Research & Educational Use Only: All peptides and compounds referenced in this guide are research chemicals documented for scientific education. This content does not constitute medical advice. All compounds should only be used for legitimate laboratory research in accordance with applicable laws. Consult a licensed physician or researcher before any use.
Common Research Protocol Mistakes
Treating investigational compounds as equivalent to FDA-approved options
Retatrutide and other investigational compounds are in ongoing trials. Phase 2 data shows promising signals, but Phase 3 results, full safety characterization, and regulatory review have not been completed. Representing them as equivalent to approved medications misrepresents the evidence hierarchy and understates the risks of unapproved compounds.
Combining approved GLP-1 agonists thinking dual coverage is additive
Semaglutide and tirzepatide both activate GLP-1 receptors. Combining them saturates the same receptor with two competing agonists, producing overlapping GI side effects without additional efficacy. There is no clinical rationale or trial data supporting dual GLP-1 agonist use, and it constitutes off-label use outside any studied protocol.
Expecting research-peptide body composition studies to replicate GLP-1 weight loss trial outcomes
GH secretagogue studies measure body composition changes (fat-to-muscle ratio) in small research populations, not total body weight reduction in large obesity trials. The evidence bases are not comparable. STEP and SURMOUNT trials enrolled thousands of participants with defined obesity criteria; secretagogue studies typically enroll tens of participants with different endpoints.
Tracking outcomes with scale weight alone in body composition research
GLP-1 agonists reduce total weight but with varying lean-to-fat ratios. DEXA scanning or waist circumference measurement provides a more accurate picture of fat loss versus lean mass change. This distinction is important for interpreting research endpoints and is standard methodology in published body composition research.
Frequently Asked Questions
Which peptide has the most weight loss evidence?
As of mid-2026, tirzepatide showed the greatest mean weight reduction in its Phase 3 SURMOUNT trials (22.5 percent in SURMOUNT-1). Semaglutide showed 14.9 percent in STEP 1. Both are FDA-approved for specific obesity indications. Retatrutide is investigational with Phase 2 data showing substantial weight reduction; its Phase 3 TRIUMPH trials are ongoing with results not yet fully published. These figures are from specific clinical trial populations and cannot be generalized to self-administered use.
Are weight loss peptides safe?
FDA-approved GLP-1 agonists (Semaglutide, Tirzepatide) have extensively characterized safety profiles from clinical trials enrolling tens of thousands of participants. Common side effects include nausea, vomiting, constipation, and GI discomfort, especially during dose titration. Rare but serious risks include pancreatitis and thyroid C-cell concerns. Research chemicals like CJC-1295 and Ipamorelin have limited human safety data and are not approved for human use. Any use of these compounds should be under appropriate clinical oversight.
What is the difference between GLP-1 agonists and GH secretagogues for body composition?
GLP-1 agonists (semaglutide, tirzepatide) reduce caloric intake through appetite suppression and slowed gastric emptying; the weight lost includes both fat and lean mass. GH secretagogues (CJC-1295 plus Ipamorelin) amplify GH pulses to drive visceral fat lipolysis while increasing protein synthesis; body composition research focuses on fat-to-muscle ratio rather than total weight. These are mechanistically distinct tools studied for different endpoints in different populations. Neither class should be compared on the assumption they can be used interchangeably.
How long do GLP-1 weight loss trials run?
FDA-approved GLP-1 agonist trials are titrated over 16-20 weeks to reach full therapeutic doses, and measurable weight loss is measured at 48-72 weeks in pivotal clinical trials. Discontinuation studies (STEP 4, SURMOUNT-4) showed rapid weight regain, establishing that ongoing treatment is necessary to maintain outcomes in the studied populations. GH secretagogue body composition studies have generally run 12-16 week protocols. AOD-9604 studies ran for 12 weeks with modest effects in that timeframe.
Why do GLP-1 peptides cause nausea?
Nausea from GLP-1 agonists results primarily from slowed gastric emptying and direct GLP-1 receptor activation in the area postrema of the brainstem. The area postrema lies outside the blood-brain barrier, making it directly accessible to circulating GLP-1 agonists. Slow dose titration over 16-20 weeks is the primary strategy used in clinical protocols to minimize GI side effects. This is a well-characterized pharmacological effect managed within the clinical prescribing context for the approved indications.
Research Peptide Vendor List
These are the research peptide vendors we track. Each supplier is scored on published certificate of analysis practice, independent testing, review record, and operating history. All compounds are sold for laboratory research use only.
- Kylo Peptides VerifiedBatch-level third-party COA3.9 from 12 reviews
- Biolongevity Labs VerifiedBatch-level third-party COA4.0 from 5 reviews
- MyBioSource VerifiedBatch-level third-party COA3.4 from 5 reviews
- Biotech Peptides VerifiedBatch-level third-party COA2.6 from 17 reviews
- AminoClub VerifiedBatch-level third-party COA3.0 from 3 reviews
- Core Peptides VerifiedBatch-level third-party COA3.0 from 3 reviews
Related Research Guides
Want to compare peptides interactively?
Use our interactive comparison tool or stack builder to design your research protocol.